TNFRSF17 and Miyoshi myopathy: An autologous second-generation BCMA-redirected CAR-T constructed on humanized alpaca-derived anti-BCMA nanoantibodies demonstrated safety and efficacy in a trial of 16 patients with r/r MM (NCT03661554).